Advanced and hereditary thyroid cancer

 

ETJ advanced medullary thyroid cancer collection

 

Advanced and hereditary thyroid cancers remain therapeutically challenging for the clinician, and novel molecularly-targeted systemic treatments are becoming the mainstay of management for those patients with disseminated disease. This topic collection focussed on recent developments in the management of people with these thyroid cancers.

If you are interested in contributing an original research article to this collection, please submit your article proposal to etj@bioscientifica.com.

 

Research articles

Calcitonin Levels in Thyroid Disease Are Not Affected by Autoimmune Thyroiditis or Differentiated Thyroid Carcinoma
Fabio Maino et al.

Cardiac Metastasis from Medullary Thyroid Cancers with Long-Term Survival under Vandetanib
Camille Buffet et al.

Medullary Thyroid Cancer Patient's Assessment of Quality of Life Tools: Results from the QaLM Study
Laura Moss et al.

Prevalence and Risk Factors of Developing Fistula or Organ Perforation in Patients Treated with Lenvatinib for Radioiodine-Refractory Thyroid Cancer
Laura Valerio et al.

Quality of Life during Treatment with Lenvatinib for Thyroid Cancer: The Patients' Perspective beyond the Medical Evaluation
Alice Nervo et al.

High Prevalence and Conservative Management of Acute Cholecystitis during Lenvatinib for Advanced Thyroid Cancer
Marta Di Stefano et al.

Poorly differentiated thyroid carcinoma: a clinician's perspective
Junyu Tong et al.

Initial clinical and treatment patterns of advanced differentiated thyroid cancer: ERUDIT study
Juan Antonio Vallejo Casas et al.

Prognostic factors to predict the efficacy of surgical interventions against brain metastasis secondary to thyroid cancer
Jihwan Yoo et al.

 

Meta analysis

Benefits and Limitations of TKIs in Patients with Medullary Thyroid Cancer: A Systematic Review and Meta-Analysis
Zoe A. Efstathiadou et al.

 

Case reports

Unusual increase in carcinoembryonic antigen despite response to selpercatinib in two patients with medullary thyroid cancer
Stéphane Bardet et al.

Significant response to pralsetinib in a medullary thyroid cancer harboring double RET variants of unknown significance
Ségolène Hescot et al.

3D-Printed Template-Guided I-125 Seed Brachytherapy: A Salvage Approach for Locoregional Refractory Recurrence of Papillary Thyroid Cancer
Zhen Gao et al.

Therapeutic Effect of Combined Dabrafenib and Trametinib Treatment of BRAF V600E-Mutated Primary Squamous Cell Carcinoma of the Thyroid: A Case Report
Tim Brandenburg et al.